Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hypertension

ClinicalTrials.gov lists 7,463 trials for Hypertension or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 178.

MeSH D006973 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 466 Phase 1/2 Phase 1/2 75 Phase 2 Phase 2 490 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 783 Phase 4 Phase 4 837 Not applicable Not applicable 2,943 Observational Observational 1,791 Phase 1 Phase 1 466 Phase 1/2 Phase 1/2 75 Phase 2 Phase 2 490 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 783 Phase 4 Phase 4 837 Not applicable Not applicable 2,943 Observational Observational 1,791

Trials per phase (log scale)

1 more section with rows

5,898 of the 7,463 trials are tagged with Hypertension itself; the rest are tagged with a narrower condition beneath it.

Get the Hypertension report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hypertension trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 22 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 392

1990: 12 trials (Observational 9, Not applicable 1, Phase 3 1, Phase 2 1) 1991: 13 trials (Observational 9, Not applicable 1, Phase 3 3) 1992: 18 trials (Observational 12, Phase 3 4, Phase 2 2) 1993: 21 trials (Observational 16, Phase 4 1, Phase 3 2, Phase 2 1, Phase 1 1) 1994: 8 trials (Observational 5, Phase 3 1, Phase 2 1, Phase 1 1) 1995: 18 trials (Observational 13, Not applicable 1, Phase 3 3, Phase 2/3 1) 1996: 8 trials (Observational 6, Not applicable 2) 1997: 17 trials (Observational 5, Not applicable 1, Phase 4 3, Phase 3 5, Phase 2 2, Phase 1 1) 1998: 34 trials (Observational 14, Not applicable 2, Phase 3 10, Phase 2 8) 1999: 30 trials (Observational 18, Phase 4 3, Phase 3 5, Phase 2 3, Phase 1 1) 2000: 50 trials (Observational 15, Not applicable 5, Phase 4 13, Phase 3 9, Phase 2 3, Phase 1 5) 2001: 52 trials (Observational 14, Not applicable 7, Phase 4 9, Phase 3 14, Phase 2 4, Phase 1 4) 2002: 67 trials (Observational 10, Not applicable 16, Phase 4 15, Phase 3 16, Phase 2 9, Phase 1 1) 2003: 119 trials (Observational 25, Not applicable 19, Phase 4 38, Phase 3 24, Phase 2 7, Phase 1/2 2, Phase 1 4) 2004: 174 trials (Observational 21, Not applicable 31, Phase 4 52, Phase 3 39, Phase 2 21, Phase 1/2 2, Phase 1 8) 2005: 198 trials (Observational 24, Not applicable 42, Phase 4 44, Phase 3 55, Phase 2/3 4, Phase 2 18, Phase 1/2 2, Phase 1 9) 2006: 249 trials (Observational 46, Not applicable 56, Phase 4 52, Phase 3 61, Phase 2/3 3, Phase 2 15, Phase 1/2 3, Phase 1 13) 2007: 251 trials (Observational 50, Not applicable 44, Phase 4 43, Phase 3 56, Phase 2/3 2, Phase 2 37, Phase 1 19) 2008: 281 trials (Observational 50, Not applicable 68, Phase 4 59, Phase 3 53, Phase 2/3 2, Phase 2 27, Phase 1/2 2, Phase 1 20) 2009: 287 trials (Observational 70, Not applicable 77, Phase 4 55, Phase 3 31, Phase 2/3 5, Phase 2 20, Phase 1/2 5, Phase 1 24) 2010: 289 trials (Observational 71, Not applicable 83, Phase 4 55, Phase 3 32, Phase 2/3 4, Phase 2 23, Phase 1/2 3, Phase 1 18) 2011: 281 trials (Observational 60, Not applicable 89, Phase 4 45, Phase 3 32, Phase 2/3 4, Phase 2 23, Phase 1/2 6, Phase 1 22) 2012: 282 trials (Other 1, Observational 59, Not applicable 97, Phase 4 37, Phase 3 31, Phase 2/3 4, Phase 2 27, Phase 1/2 5, Phase 1 21) 2013: 256 trials (Observational 61, Not applicable 94, Phase 4 26, Phase 3 24, Phase 2/3 7, Phase 2 18, Phase 1/2 3, Phase 1 23) 2014: 297 trials (Observational 69, Not applicable 117, Phase 4 36, Phase 3 26, Phase 2/3 4, Phase 2 22, Phase 1/2 3, Phase 1 20) 2015: 289 trials (Observational 67, Not applicable 123, Phase 4 35, Phase 3 15, Phase 2/3 4, Phase 2 17, Phase 1/2 5, Phase 1 23) 2016: 261 trials (Observational 68, Not applicable 106, Phase 4 24, Phase 3 19, Phase 2/3 4, Phase 2 17, Phase 1/2 4, Phase 1 19) 2017: 302 trials (Observational 97, Not applicable 130, Phase 4 26, Phase 3 16, Phase 2/3 5, Phase 2 16, Phase 1/2 2, Phase 1 10) 2018: 326 trials (Observational 75, Not applicable 167, Phase 4 22, Phase 3 19, Phase 2/3 3, Phase 2 16, Phase 1/2 2, Phase 1 22) 2019: 318 trials (Observational 70, Not applicable 173, Phase 4 20, Phase 3 19, Phase 2/3 2, Phase 2 16, Phase 1/2 3, Phase 1 15) 2020: 287 trials (Observational 87, Not applicable 136, Phase 4 15, Phase 3 18, Phase 2 12, Phase 1/2 1, Phase 1 18) 2021: 349 trials (Observational 97, Not applicable 165, Phase 4 20, Phase 3 23, Phase 2/3 3, Phase 2 12, Phase 1/2 4, Phase 1 25) 2022: 357 trials (Observational 74, Not applicable 197, Phase 4 18, Phase 3 21, Phase 2/3 1, Phase 2 17, Phase 1/2 2, Phase 1 27) 2023: 389 trials (Observational 88, Not applicable 231, Phase 4 19, Phase 3 19, Phase 2/3 4, Phase 2 8, Phase 1/2 2, Phase 1 18) 2024: 392 trials (Observational 87, Not applicable 223, Phase 4 18, Phase 3 24, Phase 2/3 1, Phase 2 11, Phase 1/2 5, Phase 1 23) 2025: 388 trials (Observational 94, Not applicable 214, Phase 4 16, Phase 3 16, Phase 2/3 2, Phase 2 22, Phase 1/2 2, Phase 1 22)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 358
2025 388
2024 392
2023 389
2022 357
2021 349
2020 287
2019 318
2018 326
2017 302

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 400 trials starting in 2026 and about 390 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 527 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 4,749 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hypertension trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 466
Phase 1/2 75
Phase 2 490
Phase 2/3 71
Phase 3 783
Phase 4 837
Not applicable 2,943
Observational 1,791
Expanded access 7

How many Hypertension trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 300
Recruiting 655
Enrolling by invitation 79
Active, not recruiting 223
Available 5

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hypertension trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 178
Novartis 147
Boehringer Ingelheim 124
Boryung Pharmaceutical Co., Ltd 80
Novartis Pharmaceuticals 77

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Hypertension? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
VALSARTAN 108
SILDENAFIL 60
NEBIVOLOL 59
IRBESARTAN 39
RAMIPRIL 38

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Amlodipine 158
HCTZ-hydrochlorothiazide 112
Telmisartan 80 107
Aliskiren 150 90
Low dose losartan 79

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hypertension trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
All-cause hospitalization 3,746 3
Hospitalizations 2,299 1
Other 1,937 5
Pneumonia 1,184 129
Number with All Cause Hospitalization in 12 months 1,136 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hypertension? (10,457)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Antihypertensive Treatments After Acute Ischemic Stroke: to Continue or Not? Hypertension (Dallas, Tex. : 1979) 2026 Yes
Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial. British journal of clinical pharmacology 2026 Yes
Antihypertensive treatment effect of two dual therapies according to sodium sensitivity. Hypertension research : official journal of the Japanese Society of Hypertension 2026 Yes
Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. Journal of the American College of Cardiology 2026 Yes
DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial. JAMA 2026 Yes

Showing 5 of 10,457 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages